Belgium's Contipharma unveils saliva-based malaria test at Medica 2026
What's the deal? Liège medtech Contipharma has unveiled Smart, an all-in-one saliva test for diagnosing malaria, at the Medica 2026 trade fair. The company says it is a world first for a rapid salivary antigen test, and validation is under way in Kinshasa, Democratic Republic of Congo.
How it works: The test uses saliva rather than a finger-prick blood sample, which could simplify screening for children and people in remote communities. Contipharma has filed a patent for the salivary antigen approach.
Why now? The need is large. The World Health Organization estimates 282 million malaria cases and 610,000 deaths worldwide in 2024, with the DRC among the hardest-hit countries.
What's the endgame? Contipharma has built its diagnostics around saliva-based testing, from PCR and antigen kits for Covid-19 to a mobile testing truck. It also received a DRC order for one million Mpox tests, signalling an established footprint in the region.
What could go wrong? Smart remains under validation, so its accuracy and real-world readiness are not yet established. The WHO still recommends parasite-based confirmation by microscopy or rapid diagnostic test before treatment, and procurement by major agencies depends on rigorous quality assessment and prequalification.
The signal: A non-invasive saliva test could lower barriers to malaria screening in the worst-affected regions. But this is an early-stage product story, not yet evidence that standard diagnosis is about to change.
Read more: lalibre.be
Image credit: "Rapid diagnostic malaria test", public domain (CC0 1.0)